Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MK6592 + docetaxel
- Development stage
- Discontinued
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
MK6592 + docetaxel is an experimental combination therapy comprised of the investigational small molecule MK6592, an Aurora kinase (AURK) inhibitor, and docetaxel, a well-established taxane-class chemotherapeutic that stabilizes microtubules and inhibits mitosis. MK6592 was developed for oncology indications, aiming to disrupt cell proliferation via inhibition of Aurora kinases, key regulators of mitotic cell division. Docetaxel is widely used in the treatment of various solid tumors and exerts its antineoplastic effects by promoting microtubule assembly and preventing disassembly, leading to cell cycle arrest and apoptosis. The combination was tested in Phase 1 studies for relapsed or refractory advanced solid tumors, but development was discontinued at an early stage.
- Other names
- MK6592MK-6592MK 6592VX-667VX667VX 667Taxotere
02
Targets
BCL-2 (BCL-2 family)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on MK6592 + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MK6592 + docetaxel.